Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorHamilton Health Sciences Corporation
About this trial
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Eligibility criteria
Qualifiers
A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP*) rare variant OR the TMEM43-p.S358L variant
Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor
Clinical ACM diagnosis or recognition of genetic carrier status for ≥ 6 months prior to screening
Disqualifiers
NYHA class IV heart failure
Ventricular scar secondary to coronary artery disease
Initiation, cessation, or dose change of a Class I or III anti-arrhythmic drug in the 3 months prior to screening
Any potentially harmful chronic liver disease
Trial design
Treatments tested in this trial
- Tideglusib
- Placebo
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Hamilton Health Sciences Corporation
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Canadian SADS
Collaborator
AMO Pharma Limited
Collaborator
Hearts in Rhythm Organization (HiRO)
Collaborator
Population Health Research Institute
Collaborator
Source ClinicalTrials.gov